[1] Brettschneider J, Petzold A, Süssmuth S D, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS [J]. Neurology, 2006, 66(6): 852-856.
[2] Ganesalingam J,An J,Bowser R, et al. pNfH is a promising biomarker for ALS [J]. Amyotroph Lateral Scler Frontotemporal Degener, 2013, 14(2): 146-149.
[3] Süssmuth S D,Tumani H,Ecker D, et al. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum[J]. Neurosci Lett, 2003, 353(1): 57-60.
[4] Grossman M,Elman L,McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis[J]. JAMA Neurol,2014, 71(4): 442-448.
[5] Wilke C,Deuschle C,Rattay T W, et al. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis[J]. Neurobiol Aging, 2015, 36(2): 1072-1074.
[6] Calingasan N Y,Chen J,Kiaei M, et al. Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients[J]. Neurobiol Dis, 2005, 19(1-2): 340-347.
[7] Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles [J]. Int J Biochem Cell Biol, 2001, 33(7): 637-668.
[8] Carilho R,de Carvalho M,Kuehl U, et al. Erythropoietin and amyotrophic lateral sclerosis: plasma level determination[J]. Amyotroph Lateral Scler, 2011, 12(6): 439-443.
[9] Ryberg H,Sderling A S,Davidsson P, et al. Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer’s disease[J]. Neurochem Int, 2004, 45(1): 57-62.
[10] Ihara Y,Nobukuni K,Takata H, et al. Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation[J]. Neurol Res, 2005, 27(1): 105-108.
[11] Kokic＇ A N,Stevic＇ Z,Stojanovic＇ S, et al. Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients[J]. Redox Rep, 2005, 10(5): 265-270.
[12] Simpson E P,Henry Y K,Henkel J S, et al. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden [J]. Neurology, 2004, 62(10): 1758-1765.
[13] Jones S D, Drake D J. Case series of undetected intranasal impression material in patients with clefts [J]. Br J Oral Maxillofac Surg, 2013, 51(3): e34-36.
[14] Feneberg E,Steinacker P,Lehnert S, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases [J]. Amyotroph Lateral Scler Frontotemporal Degener, 2014, 15(5-6): 351-356.
[15] Garbuzova-Davis S, Saporta S, Sanberg P R. Implications of blood-brain barrier disruption in ALS[J]. Amyotroph Lateral Scler, 2008, 9(6): 375-376.
[16] Kuncl R W,Bilak M M,Bilak S R, et al. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis[J]. J Neurochem, 2002, 81(1): 178-184.
[17] Devos D,Moreau C,Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients[J]. Neurology, 2004, 62(11): 2127-2129.
[18] Ilzecka J. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis [J]. Clin Neurol Neurosurg, 2004, 106(4): 289-293.
[19] Ahmed Z,Mackenzie I R,Hutton M L, et al. Progranulin in frontotemporal lobar degeneration and neuroinflammation [J]. J Neuroinflammation, 2007, 4: 7.
[20] Philips T,De Muynck L,Thu H N, et al. Microglial upregulation of progranulin as a marker of motor neuron degeneration[J]. J Neuropathol Exp Neurol, 2010, 69(12): 1191-1200.
[21] Wilson M E,Boumaza I,Lacomis D, et al. Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis [J]. PLoS One, 2010, 5(12): e15133.
[22] Di Rosa M,Malaguarnera G,De Gregorio C, et al. Modulation of chitotriosidase during macrophage differentiation [J]. Cell Biochem Biophys, 2013, 66(2): 239-247.
[23] Zhou J Y,Afjehi-Sadat L,Asress S, et al. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach[J]. J Proteome Res, 2010, 9(10): 5133-5141.
[24] Gray E,Larkin J R,Claridge T D, et al. The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis [J]. Amyotroph Lateral Scler Frontotemporal Degener, 2015, 16(7-8): 456-463.
[25] Valentino F,Bivona G,Butera D, et al. Elevated cerebrospinal fluid and plasma homocysteine levels in ALS [J]. Eur J Neurol, 2010, 17(1): 84-89.
[26] Hozumi I,Hasegawa T,Honda A, et al. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases[J]. J Neurol Sci, 2011, 303(1-2): 95-99.
[27] Zhao Z,Lange D J,Ho L, et al. Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis[J]. Int J Med Sci, 2008, 5(2): 92-99.
[28] Benigni M,Ricci C,Jones A R, et al. Identification of miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis patients[J]. Neuromolecular Med, 2016, 18(4):551-560.
[29] Johansson A,Larsson A,Nygren I, et al. Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis [J]. Neuroreport, 2003, 14(14): 1867-1869.
[30] Kern M A,Friese M,Grundstrom E, et al. Amyotrophic lateral sclerosis: evidence for intact hepatocyte growth factor/met signalling axis[J]. Cytokine, 2001, 15(6): 315-319.
[31] Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis [J]. Acta Neurol Scand, 2006, 114(3): 205-209.
[32] Rafiq M K,Lee E,Bradburn M, et al. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis[J]. Eur J Neurol, 2016, 23(6):1071-1078.
[33] Abraham A, Drory V E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis [J]. J Neurol, 2014, 261(6): 1133-1138.
[34] Ilzecka J. Serum soluble OX40 in patients with amyotrophic lateral sclerosis [J]. Acta Clin Croat, 2012, 51(1): 3-7.
[35] Edri-Brami M,Rosental B,Hayoun D, et al. Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells [J]. PLoS One, 2012, 7(5): e35772.
[36] Matus S,Valenzuela V,Medinas D B, et al. ER dysfunction and protein folding stress in ALS [J]. Int J Cell Biol, 2013, 2013: 674751.
[37] Anand A,Gupta P K,Prabhakar S, et al. Analysis of smoking and LPO in ALS[J]. Neurochem Int, 2014, 71: 47-55.
[38] Lu C H,Allen K,Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis [J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(4): e244.
[39] Houi K,Kobayashi T,Kato S, et al. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis [J]. Acta Neurol Scand, 2002, 106(5): 299-301.
[40] Lacomblez L,Doppler V,Beucler I, et al. APOE: a potential marker of disease progression in ALS [J]. Neurology, 2002, 58(7): 1112-1114.